test
Related news for (CMPS)
- Compass Pathways to participate in upcoming Oppenheimer investor conference
- How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
- Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023